ArticleInternational journal of computer assisted radiology and surgery2022
Non-invasive precise staging of liver fibrosis using deep residual network model based on plain CT images.
Article in International journal of computer assisted radiology and surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Multimodal artificial intelligence models for liver fibrosis staging: a scoping review.Abdominal radiology (New York) · 2026Review
- Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe aim of this study was to explore the application of five-class deep residual network models based on plain CT images and clinical features for the precise staging of liver fibrosis.
methodsThis retrospective clinical study included 347 patients who underwent liver CT, with pathological staging of liver fibrosis as the gold standard. We established three ResNet models to stage liver fibrosis. The output diagnosis labels of models were 0, 1, 2, 3 and 4, which correspond to F0, F1, F2, F3, and F4 stages. Confusion matrices were used to evaluate the performances of models to precisely stage liver fibrosis. The performance for diagnosing cirrhosis (F4), advanced fibrosis (≥ F3) and significant fibrosis (≥ F2) of models was evaluated with receiver operating characteristic (ROC) analyses.
resultsThe kappa coefficients of the five-class ResNet model (based on plain CT images), the five-class ResNet clinical model (based on clinical features), and the five-class mixed ResNet model (based on plain CT images and clinical features) for precise staging liver fibrosis were 0.566, 0.306, and 0.63, respectively. The recall rates and precision rates for F0, F1, F2, and F3 of three models were lower than 60%. The ROC AUC values of the five-class ResNet model, the five-class ResNet clinical model, and the five-class mixed ResNet model for diagnosing cirrhosis, advanced fibrosis, and significant fibrosis were 0.95, 0.88, and 0.82, 0.80, 0.72, and 0.70, 0.95, 0.90, and 0.83, respectively.
conclusionsThe five-class ResNet models are of high value in the diagnosis of liver cirrhosis, advanced liver fibrosis, and significant liver fibrosis. However, for the precise staging of liver fibrosis, the models cannot accurately distinguish other liver fibrosis stages except F4. Plain CT images combined with clinical features have the potential to improve the performance of the ResNet models in diagnosing liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.